Case Report: Termination of unplanned pregnancy led to rapid deterioration of non-small-cell lung cancer during osimertinib treatment

Frontiers in Oncology

Oncology

Kexun Zhou¹  Yongsheng Wang²  Qizhi Ma²  Pei Shu² 

[1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China

[2]Division of Thoracic Tumor Multimodality Treatment, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China

关键词: pregnancy;    non-small-cell lung cancer;    epidermal growth factor receptor;    tyrosine kinase inhibitor;    deterioration;   

DOI  :  10.3389/fonc.2023.1073938

 received in 2022-10-24, accepted in 2023-09-20,  发布年份 2023

来源: Frontiers

【 摘 要 】

We present a case of a woman with non-small-cell lung cancer (NSCLC) who experienced disease progression during treatment with the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) osimertinib due to an unplanned pregnancy. Given the risk of tumor progression, the patient underwent an artificial abortion. However, disease deterioration occurred shortly after termination of the pregnancy, with severe chest pain, increased dyspnea, and pleural effusion. After positive rescue measures, including emergency thoracic drainage, thoracentesis, and oxygen uptake, her symptoms improved. Considering pregnancy as an immune escape physiological process, the patient continued treatment with osimertinib, and a partial response (PR) lasting 16 months was observed. Therefore, this case highlights the importance of being vigilant about the rapid development of the tumor after delivery in pregnant patients with EGFR-mutation lung cancer and taking preventive measures to cope with various emergencies.

【 授权许可】

Unknown   
Copyright © 2023 Ma, Shu, Zhou and Wang